We have demonstrated that human plasma contains a heparin-dependent inhibitor of thrombin that is distinguishable from antithrombin III (AT III). When a 1:50 dilution of plasma was incubated with greater than or equal to 0.01 U/ml heparin and 1 U/ml 125I-thrombin, the labeled thrombin B-chains became incorporated into two complexes of Mr-96,000 and Mr-85,000 that were separated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate and beta-mercaptoethanol. Neither complex was detectable at heparin concentrations less than 0.01 U/ml. When a limiting amount of 125I-thrombin was present, the proportion of radioactivity incorporated into each of the two complexes varied with the heparin concentration. Thus, the Mr-85,000 complex predominated at 0.01-5 U/ml heparin, whereas the Mr-96,000 complex predominated at 5-100 U/ml heparin. The Mr-85,000 complex reacted with antibodies to human AT III and comigrated with the purified thrombin-AT III complex. The Mr-96,000 complex did not react with antibodies to AT III or to alpha 1-antitrypsin, and it was detected in normal quantities after incubating 125I-thrombin with plasma immunodepleted of AT III, alpha 2-antiplasmin, alpha 2-macroglobulin, C1 inactivator, alpha 1-antichymotrypsin, or inter-alpha-trypsin inhibitor. The protein that combines with thrombin to form the Mr-96,000 complex was estimated to be present at a minimum concentration of 90 +/-26 micrograms/ml (mean +/-SD) in identical to any of the known plasma protease […]
INTRODUCTION
Heparin has been known for many years to be a potent anticoagulant and is widely used in the treatment of thromboembolic disorders in man (1) . It is generally accepted that heparin exerts its anticoagulant effect by activating the plasma protein antithrombin III (AT III)' (formerly called "heparin cofactor") (2) . AT III inhibits thrombin and other coagulation proteases (Factors Xa, IXa, XIa, XIIa, and kallikrein) by forming 1:1 stoichiometric complexes with each protease (2) . That the complexes are stable in denaturing agents suggests that a covalent bond is formed between the protease and the inhibitor and allows detection of the complexes in sodium dodecyl sulfate (SDS) polyacrylamide gels.
It is clear that heparin accelerates the rate at which AT III reacts with various proteases in vitro. In the case ofthrombin, the second-order rate constant ofcomplex formation increases from 4.3 x 105 M-1 min-' in the absence of heparin to 8 x 108 M-l min-' at optimal heparin concentrations (3) . None of the other recognized protease inhibitors in plasma2 is known to be stimulated by heparin, with the possible exception of C1 inactivator (5) , which does not inhibit thrombin (6) . On the other hand, several previous reports have claimed to separate from AT III a thrombin inhibitor with heparin cofactor activity, although the material responsible for this activity was neither purified nor characterized by immunological techniques (7) (8) (9) . Thus, the existence of a heparin cofactor apart from AT III has remained in doubt.
In the present investigation, we have incubated 125I-labeled thrombin with plasma and separated the 'Abbreviations used in this paper: AT III, antithrombin III; SDS, sodium dodecyl sulfate.
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Mr 85000-' Mr 72,000--4 Mr 32,000-'-W * Tracking dye e _ FIGURE 1 Interaction of 1251-thrombin with plasma and purified AT III. Samples contained either plasmiia (1 ul) or AT III (1 ,ul of a 200-,ug/ml stock solution) in a total volume of 50 ,ul of 0.15 M NaCl, 0.05 M Tris-HCl, pH 7.4 . 1251-thromiibin and heparin at final concentrations of 1 U/ml and 5 U/ml, respectively, were also present as indicated. After a 10-mim incubation at 25°C, each sample was prepared for electrophoresis and autoradiography as described in Methods. The autoradiogram is shown. (a) '251-thrombin, (b) 1251-throllmbin + plasma, (c) 125I-thrombin + plasmiia + heparin, (d) 1251_ thrombin + purified AT III + heparin. resulting inhibitor-protease complexes by SDS polyacrylamide gel electrophoresis. In this manner we have demonstrated the presence of a previously unrecognized thrombin inhibitor with heparin cofactor activity. The new inhibitor is immunologically distinct from AT III and from all of the other known protease inhibitors in plasma. The inhibitor is present in plasma at a concentration somewhat lower than that of AT III. In the presence of relatively high concentrations of heparin, however, thrombin forms complexes preferentially with the new inhibitor.
METHODS
Materials. Blood was drawn from normal volunteers into plastic syringes containing 6 mM EDTA (final concentration). Cells were removed by centrifugation, and the plasma was stored at -20°C before use. Heparin derived from porcine intestinal mucosa (Panheprin, Abbott Diagnostics, Diagnostic Products, North Chicago, Ill., 1,000 U. S. Pharmacopeia U/ml; or Lipo-Hepin, Riker Laboratories, Inc., Northridge, Calif., 20,000 U. S. Pharmacopeia U/ml) was diluted in buffer containing 0.15 M NaCl and 0.05 M Tris-HCl, pH 7.4, immediately before use; the biological activity was assumed to be that stated by the manufacturer.
According to the carbazole assay for uronic acid (10), the specific activities of the two heparin preparations were 159 U/mg (Abbott Diagnostics) and 144 U/mg (Riker). Rabbit antisera directed against human AT III, al-antitrypsin, al-anitichymiiotrypsin, a2-macroglobulin, Cl inactivator, and inter-a-trypsin inhibitor were purchased from Calbiochem-Behring Corp., American Hoechst, La Jolla, Calif. Rabbit antiseruim directedl against human a2-antiplasmin was purchased from Nordic Immunological Laboratories (USA), Sani Clemiienite, Calif. Apiezon A oil was obtained from James B. Biddle Co., Plymouth Meeting, Pa.
Proteins. Humlan prothrombin was prepared by the method of Miletich et a]. (11) . Prothrombin was activated using Taipani snake venom (12) and thrombin was subsequenltly isolate(l by chromatography on Amberlite CG-50 resini (13) . Thrombin activity was measured in a fibrinogen-clotting assay (13) standardized with U. S. Standard Thrombin, Lot J, ol)tained from Dr. D. L. Aronson, Bureau of Biologics, Food and( Drug Administration, Bethesda, Md. Proteini collcenltratioin was determined by ultraviolet absorbance, as-sUminlg E28,'1' = 18.3 for thrombin (13) . The specific activity ranlgedl fromii 2,400 to 2,700 U/mg thrombin. The preparationi was homogeneous by SDS polyacrylamide gel electrophoresis, which indicated the absence of detectable quantities of 8and y-thrombin (13) .
Humani AT III was purified by the method of Thaler anid Schmer (14) . In a standard clotting assay, the preparation inhibited 1,500-2,000 U of thrombin/mg of AT III, onl the assumiption of E280'% = 5.7 for AT III (15) . The AT III was homogeneous and had an Mr of 59,000 by SDS polyacrylamiidle gel electrophoresis.
Ioditnation of thrombitn. Thrombin was iodinated by the chloramiiine-T method described previously (16) , modified to include 20 ,uM unlabeled Nal in the reaction mixture. This resulted in the incorporation of -0.5 atom of I/molecule ofthrombin, and in a specific radioactivity of2-4 x 106 cpm/U thrombin. The 1251-thrombin had >90% of the specific clotting activity of the unlabeled starting material. In parallel incubations conitaining 10 ,tg/ml of purified AT III and 0.08 ,g/ml of either '251-thrombin or unlabeled thrombin, the rates of inactivatioin of the two thrombins were identical (data not shown). The second-order rate constant calculated for the inactivation of 1251-thrombin by AT III was 5.3 x 105 M-1 min-', in agreement with the value for unlabeled thrombin reported by others (3) .
SDS gel electrophoresis. Samples were heated at 100°C for 2 min with an equal volume of a solution containing 4% SDS, 10% ,f-mercaptoethanol, 20% glycerol, and 0.125 M Tris-HCI, pH 6.8. Electrophoresis was performed with slab gels containing 7.5% polyacrylamide in the running gel and 4% polyacrylamide in the stacking gel according to the procedure of Laemmli (17) . The gels were fixed and stained with a solution containing 0.25% Coomassie Blue G-250, 10% acetic acid, and 50% methanol. The gels were destained with a solution containing 10% acetic acid and 25% ethanol, and dried with a Hoefer model SE540 slab gel dryer (Hoefer Scientific Instruments, San Francisco, Calif. Immediately before use, the bacteria were washed with 0.25% Nonidet P-40 in 0.15 M NaCl, 0.05 M Tris-HCl, pH 7.4, and resuspended in the same buffer without detergent at a concentration of 8-10% (packed cell volume). Bacteria were coated with antibodies specific for one of the plasma protease inhibitors by incubating 0.5 ml of the S. aureus suspension with 0.5 ml of rabbit antiserum for 2 h at 25°C. The bacteria were washed in the above buffer (without detergent) to remove unbound serum proteins and then sedimented at 12,000 g for 10 min to produce a tightly packed pellet. 50 ,ul of human plasma was then mixed with the bacterial pellet (-50 ,ul, packed cell volume) and allowed to incubate for 2 h at 25°C. The bacteria were removed by centrifugation and the absorbed plasma was stored at -20°C. Protein concentrations of the absorbed plasma samples were measured by the Lowry method (19) and found to be -85% of that of the starting plasma, which indicates a minor degree of dilution of the plasma during the absorption procedure.
Ouchterlony analysis. Double immunodiffusion was performed with 1%-agarose plates prepared by standard methods (20) . Diffusion was allowed to proceed for 24-48 h in a humidified chamber at 25°C, and the plates were then photographed. In some cases, the plates were washed, dried, and stained for protein with Coomassie Blue R-250.
Immunoassay of AT III. AT III concentration in plasma was determined by radial immunodiffusion with agar plates containing antisera to human AT III (M-Partigen plates, Calbiochem-Behring Corp.) (21) . The assay was standardized with purified AT III.
RESULTS
125I-Thrombin preparation. Thrombin consists of two polypeptide chains linked by a disulfide bond.
They include the A-chain (Mr 4,600) and the B-chain (M, 32,000), the latter containing the active center serine residue of the protease (13) . In reduced SDS polyacrylamide gels, the 1251-thrombin used in the experiments to follow gave the pattern shown in Fig. la. Most of the radioactivity (73-84% in different preparations) was present as a single band at the position of the B-chain. The remaining 16-27% of the radioactivity migrated with the tracking dye and was assumed to represent the dissociated A-chain.
Heparin-dependent complexes of '251-thrombin and plasma proteins. When 1251-thrombin was incubated with plasma (diluted 1:50) in the absence of heparin, 20% of the 125I became incorporated into several complexes of Mr 72,000-200,000 in reduced SDS gels (Fig. lb) . Bands representing the uncomplexed Aand B-chains contained 17 and 63% of the 1251, respectively. The complexes observed in this experiment were not characterized further. 7% of the 1251, however, was found in bands of Mr 72,000 and 85,000, which probably represent complexes of 1251-thrombin with AT III, as shown below. This is precisely the extent of complex formation with AT III expected after a 10-min incubation, on the assumption of a second-order rate constant of 2.07 x 103 M-1 s-1 (22) and a concentration of 4,ug AT III/ml in the incubation mixture. A different pattern was observed when 5 U/ml heparin was included in the incubation (Fig. 1c ). Under these conditions, 50% of the radioactivity was found in three complexes of Mr 72,000, 85,000, and 96,000. An additional 15% of the 1251 was distributed uniformly throughout the area of the gel between the Mr-72,000 and Mr-32,000 bands (discussed below). There was a concomitant reduction in the amount of radioactivity at the position of the thrombin B-chain (now only 18% of the total counts per minute), whereas the radioactivity at the tracking dye did not change significantly when compared with the incubation without heparin. Control incubations containing 1251-thrombin and heparin without plasma did not form complexes (not shown). The observed complexes, therefore, appear to result from covalent bond formation between plasma proteins and the B-chain of thrombin.
The Mr-72,000 and Mr-85,000 bands in Fig. Ic contained 2/3 of the complexed B-chain radioactivity, and they comigrated with the products formed when Heparin-dependent Protease Inhibitor 591 FIGURE 3 Ouchterlony analysis of inhibitor-depleted plassmas. Plasma samples were absorbed with antisera to specific protease inhibitors and immunodiffusion was performed as described in Methods. In each case, the center well contained 5 ,ul of the antiserum used to absorb the plasma; wells 1, 2, and 3 contained 5 gl of control unabsorbed plasma (undiluted, 1:2, and 1:4, respectively); and wells 4, 5, and 6 contained 5 ,lI of absorbed plasma (undiluted, 1:2, and 1:4). Antisera to the following inhibitors were used: a, a2-antiplasmin; b, al-antitrypsin; c, a2-macroglobulin; d, antithrombin III; e, Cl inactivator; f, al-antichymotrypsin; and g, inter-a-trypsin inhibitor. Plates b andf were dried and stained before being photographed.
1251-thrombin was incubated with an amount of purified AT III equal to that present in the plasma sample (Fig. ld) . The two bands had approximately the same apparent molecular weights as the intact thrombin-AT III complex and the major degradation product of this complex reported by others (23, 24) . In subsequent experiments (Figs. 2, 4 , and 5) heparin was preincubated with plasma or AT III for 1 min before the addition of 125I-thrombin, and the Mr-72,000 band was no longer seen. The M,-96,000 band shown in Fig. lc contained -1/3 of the complexed B-chains in the presence of 5 U/ml heparin. The band was virtually undetectable in incubations without heparin ( Fig. lb) and did not form in the reaction of purified AT III and '25Ithrombin (Fig. ld) . Since electrophoresis was carried out in the presence of SDS and ,8-mercaptoethanol, it is unlikely that the Mr-96,000 band is a degradation product of the Mr-85,000 thrombin-AT III complex. These results suggest that plasma contains in addition to AT III a second protein capable of forming a complex with thrombin in the presence of heparin.
Lack of immunoreactive AT III in the Mr-96,000 complex. Alternatively, we considered that the Mr, 96,000 band might contain a precursor of AT III or result from interaction of the thrombin-AT III complex with a third plasma component. In either case the complex might have been found (although not necessarily) to contain antigenic determinants in common with native AT III. Fig. 2 demonstrates that this was not the case. Although the Mr-85,000 complex was quantitatively removed from plasma with antiserum to AT III and protein A-bearing staphylococci (25) , >90% of the Mr-96,000 complex remained in the supernate (Fig. 2, a and b ). Doubling the quantity of antiserum and staphylococci did not result in removal of more of the M,-96,000 complex (not shown).
The Mr-85,000 complex prepared from i25I-thrombin and purified AT III was absorbed as expected under identical conditions (Fig. 2, c and d) . When nonimmune rabbit serum or antiserum against human alantitrypsin (Fig. 2 , e and f) was substituted for anti-AT III antiserum, neither complex was found in the bacterial pellet. Formation of the Mr-96,000 complex in plasma samples depleted of known protease inhibitors. We next absorbed aliquots of plasma with antibodies directed against individual protease inhibitors (for details see Methods), and we assayed each absorbed plasma for the ability to form complexes with 125I1 thrombin. The effectiveness of the absorption procedure was first confirmed by double immunodiffusion analysis. Fig. 3 demonstrates that a 1:4 dilution of unabsorbed plasma formed a visible precipitin line when allowed to react with antiserum to each of the inhibitors tested. In contrast, undiluted samples of plasma that had been absorbed with antibodies against a2-antiplasmin, a2-macroglobulin, antithrombin III, Cl inactivator, al-antichymotrypsin, and inter-a-trypsin inhibitor failed to form precipitin lines with the absorbing antisera. When the -15% dilution ofthe plasma samples during absorption (see Methods) is taken into account, Fig. 3 indicates substantial (i.e., >%) depletion of the inhibitors from these plasma samples. a-lantitrypsin, which is present in plasma at an 8-to 56fold greater molar concentration than any of the other inhibitors (4), was not effectively removed by this technique (Fig. 3b) .
When the absorbed plasma samples were incubated with 125I-thrombin and heparin, the Mr-96,000 complex was formed in each case (Fig. 4, a-g) . The Mr-85,000 complex was also present as expected, except in the plasma sample depleted of AT III (Fig. 4d) . The radioactivity in the Mr-96,000 band in each of the absorbed plasma samples was 71-93% of that present in unabsorbed plasma (Fig. 4h ). It is important to note that a saturating concentration of 125I-thrombin (see below) was used to maximize complex formation in these incubations. With the exception of al-antitrypsin, for which the data are inconclusive, the experiments in Figs. 3 and 4 indicate that the Mr-96,000 complex does not result from interaction of 125I1 thrombin with any of the known protease inhibitors of plasma.
Heparin-dependence of the Mr-96,000 complex compared with that of the thrombin-AT III complex. We determined the extent of complex formation when 1251_ thrombin was added to plasma, purified AT III, or AT III-depleted plasma in the presence of various concentrations of heparin. When a limiting amount of '25I-thrombin was added to plasma (Fig. 5, a Fig. 1 after a 1-min preincubation with 0-100 U/ml heparin. Electrophoresis and autoradiography were performed as described in Methods. Selected bands identified by autoradiography (bracketed) were cut out of the dried gels and counted for 125I. The total 125j-thrombin B-chain counts per minute was assumed to be the sum of the counts per minute found in bands above the tracking dye (TD). Panels A, C, and E show the percentage of the total B-chain counts per minute found in the following bands: 0, Mr-96,000 complex; *, Mr-85,000 complex; O, area between the M,-85,000 and Mr-32,000 bands; 0, area between the Mr-96,000 and Mr-32,000 bands. Panels B, D, and F show the autoradiograms.
concentrations, a faint Mr-96,000 band was also observed. Increasing the concentration of heparin from 0.1 to 20 U/ml resulted in a substantial increase in the amount of radioactivity in the Mr-96,000 band and a concomitant decrease in the intensity of the Mr, 85,000 band. At concentrations >20 U/ml, the proportion of "-5I counts per minute in the two bands did not change. Identical results were obtained with heparin preparations from two commercial sources (see Methods).
Preliminary experiments in which 125I-thrombin (1 U/ml) was added to whole blood collected directly into syringes containing various amounts of concentrated heparin have yielded qualitatively similar results,3 although the concentrations of heparin re-3D. M. Tollefsen and M. K. Blank, unpublished observation.
Heparin-dependent Protease Inhibitor 593 quired to activate both the new inhibitor and AT III appeared to be two-to threefold greater than those in Fig. 5, a and b .
Studies in which purified AT III was substituted for plasma ( Fig. 5 , c and d) indicated (a) that the extent of formation of the Mr-85,000 complex was maximal at 0.01 U/ml of heparin and did not decrease with higher heparin concentrations, and (b) that the Mr-96,000 complex did not form even at the highest concentrations of heparin. Additional experiments using AT III-depleted plasma under identical incubation conditions (Fig. 5 , e and f) demonstrated maximal formation of the Mr-96,000 complex at a heparin concentration of 1 U/ml; as in Fig. 4d , no band corresponding to the thrombin-AT III complex was seen.
Although not readily apparent from the autoradiograms in Fig. 5 , a significant amount of radioactivity was present in the area of the gels between the Mr-85,000 and Mr-32,000 bands. As shown in Fig. 5 a, c, and e (open symbols) the radioactivity in this region paralleled that present in the Mr-85,000 complex but not in the Mr-96,000 complex, and it may thus represent dissociation of a fraction of the thrombin-AT III complexes (40-50%) during electrophoresis. This phenomenon has been described previously and may be connected with the presence of nucleophiles in the Laemmli running gel (26) . Initial attempts to separate the two complexes by electrophoresis in neutral phosphate buffers have been unsuccessful. 3 Estimation of the quantity of the new heparindependent inhibitor in plasma. By increasing the amount of 1251-thrombin incubated with a fixed quantity of plasma in the presence of 5 U/ml heparin, we demonstrated saturation of both the Mr-85,000 and Mr-96,000 complexes in SDS gels. The amount of thrombin incorporated into each complex was calculated from the specific radioactivity of the 1251_ thrombin B-chain. Analysis of samples from 16 normal subjects revealed the following: 46 + 13 ,ug (mean + SD) of thrombin in the Mr-96,000 complex and 93+13 ,g of thrombin in the Mr-85,000 complex/ml of plasma at saturation. The plasma concentrations of the new inhibitor and AT III were then estimated from these values, on the assumption of a 1:1 molar complex of thrombin and inhibitor in each case and molecular weights of 36,600 (13) , 59,000 (see Methods), and 72,000 (see Discussion) for thrombin, AT III, and the new inhibitor, respectively. Thus, we calculated a concentration of 150 +21 ,ug/ml for AT III and 90 +26 ,g/ml for the second heparin cofactor. These values, particularly that of AT III, should be considered minimum estimates of the true plasma concentrations, as the dissociated '251-thrombin was ignored in this calculation. Indeed, a 50% higher value for the concentration of AT III (225±+32 ,tg/ml) was obtained by assaying the same plasma samples by radial immunodiffusion.
DISCUSSION
Our results indicate that human plasma contains a substantial quantity of an unidentified heparin-dependent inhibitor of thrombin. Like antithrombin III (23) , the new inhibitor forms a complex with the thrombin B-chain that is stable in the presence of SDS and P-mercaptoethanol at 100°C. We have shown that thrombin treated with diisopropylfluorophosphate (16) or hirudin (27) to block the proteolytic active site of the molecule fails to form a complex with the new inhibitor in plasma.3 These experiments are consistent with the formation of a covalent bond between the protease and the inhibitor and suggest that the active site of thrombin is required to form the complex (cf. 23 and 28) .
The new inhibitor differs from AT III in the following respects: (a) It combines with thrombin to form a complex of Mr 96,000 in reduced SDS polyacrylamide gel electrophoresis (Fig. 1) ; this complex migrates more slowly than the thrombin-AT III complex (Mr 85,000). (b) The Mr-96,000 complex does not form when thrombin is allowed to react with purified AT III in the presence or absence of heparin. (c) Antibodies directed against human AT III do not react with the Mr-96,000 complex (Fig. 2) . (d) Finally, the Mr-96,000 complex is formed when thrombin is incubated with plasma immunologically depleted of AT III (Figs. 4 
and 5).
Additional experiments established that the new inhibitor is not identical to any ofthe other known plasma protease inhibitors. Thus, the Mr-96,000 complex forms in approximately normal amounts in plasma samples immunologically depleted of a2-antiplasmin, a2-macroglobulin, Cl inactivator, al-antichymotrypsin, or intera-trypsin inhibitor (Fig. 4) . Although we were unable to remove al-antitrypsin from plasma by this technique, we have shown that the Mr-96,000 complex does not react with antibodies directed against alantitrypsin ( Fig. 2) and that the complex between thrombin and al-antitrypsin migrates slightly more rapidly in SDS gels than the thrombin-AT III complex.3 In addition, the Mr-96,000 complex was found in the plasma of two patients with combined Factor V/VIII deficiency,3 which indicates that the complex is not due to the inhibitor of protein C recently described by Marlar and Griffin (29) . It is also clear that the new inhibitor is not identical to "protease-nexin," the heparin-dependent thrombin-binding protein of fibroblasts described by Baker et al. (30) , since the apparent molecular weights of the two complexes are quite different (96,000 vs. 68,000).
In the experiments illustrated in Fig. 5 , we have allowed the reaction of a limiting amount of thrombin with plasma to go to completion in the presence of varying concentrations of heparin. The simplest interpretation of the results is that at higher heparin concentrations thrombin reacts more rapidly with the new inhibitor than with AT III. Heterogeneous heparin preparations derived from porcine intestinal mucosa contain many molecules that are inactive toward AT III (3). Whether the same subfractions of heparin activate both AT III and the new inhibitor remains to be determined. The observation that the new inhibitor is fully activated at 1 U/ml heparini in AT III-depleted plasma compared with 20 U/ml in unabsorbed plasma (Fig. 5, a and e ) suggests that the two antithrombins might be competing for the same biologically active heparin species. Alternatively, as Jordan et al. (3) have pointed out, the rate at which AT III reacts with thrombin actuallv decreases at high heparin concentrations. This might allow the reaction with the new inhibitor to predominate.
At present, it is reasonable to assume that at levels of heparin achieved therapeutically by continuous intravenous infusion (i.e., 0.1-1.0 U/ml) (1), AT III is the major activated antithrombin in the plasma. The results shown in Fig. 5 support this hypothesis. It is unknown whether heparin secreted from mast cells or cell-surface mucopolysaccharides activate the new inhibitor. Thus, the two heparin-dependent antithrombins may be activated under different circumstances in vivo.
Previous investigators have separated plasma proteins by ion-exchange chromatography or electrophoresis and have claimed to resolve heparin cofactor activity from AT III (7) (8) (9) . Although in general agreement with these reports, our studies differ in two important respects. We added thrombin directly to plasma and then separated the resulting complexes under denaturing conditions, thus minimizing the likelihood of artifacts such as proteolysis that might occur during the fractionation of plasma. Furthermore, we characterized the complexes immunologically.
Our results are at variance with more recent reports claiming that AT III accounts for virtually all of the heparin-dependent antithrombin activity ofplasma. Rosenberg and Damus (23) reported that 92% of the heparin cofactor activity of heat-defibrinated plasma was removed by anti-AT III immunoglobulins. Preliminary experiments from our laboratory indicate that the new heparin-dependent inhibitor is substantially inactivated under the conditions of heat defibrination.3 Holmer et al. (31) have also used antibodies to remove AT III from plasma. They found essentially no heparin cofactor activity in the AT IIIdepleted plasma when tested with 0.04 U/ml heparin.
Our results indicate that higher heparin concentrations are required to activate the new inhibitor. Recently, Hoogendoorn et al. (32) have removed AT III from plasma by absorption to heparin-Sepharose and have found that the absorbed plasma still had a prolonged thrombin time and activated partial thromboplastin time in the presence of heparin. Unfortunately, nio attempt was made to quantify the capacity of the absorbed plasma to inactivate thrombin.
We recently have purified the protein that reacts with thrombin to form the Alr-96,000 complex in plasma. 4 The purified inhibitor has an Mr of 72,000 in the Laemmli gel system and does not react with antibodies to any of the recognized plasma protease inhibitors.2 It inhibits the proteolytic and amidolytic activity of thrombin by forming a 1:1 molar complex with the protease. The rate of complex formation increases >1,000-fold in the presence of heparin. Stuidies are in progress to elucidate the specificity of the new inhibitor with respect to various proteases and muciopolysaccharides. The physiological role ofthe nlew inhibitor remains to be defined.
